The global paraganglioma market size is estimated to be valued at USD 373.2 Million in 2025. It can reach a valuation of USD 425.8 Million by 2032, by exhibiting a CAGR of 1.9% throughout the forecast period (2025-2032).
The cases of rare tumors and advances in diagnostic technologies can drive the market growth. Increasing investments in the research of rare diseases can fuel the development of orphan drugs and entice private players to take an interest in the disease.
However, the high costs of treatment of paraganglioma can impede the market growth.
Key Market Insights
The paraganglioma market is expected to be shaped by next-generation sequencing (NGS) and the growing use of AI in diagnostic radiology.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/paraganglioma-market
Paraganglioma Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 373.2 Million |
|
Estimated Value by 2032 |
USD 425.8 Million |
|
Growth Rate |
1.9% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The awareness of neuroendocrine tumors like paraganglioma and the demand for innovative therapies is expected to drive the market growth. The advances in NGS for the diagnosis of hereditary paragangliomas can improve survival rates and proactive monitoring of the disease. Advanced imaging techniques like F-DOPA PET scans for diagnosing the precise localization of tumors can facilitate the market growth.
Targeted research on paraganglioma for the identification of specific genetic mutations and research into SDHx-mutated tumors can bode well for the market. The targeting of tumor-specific pathways for reducing damage to healthy tissue and the use of binding agents to eliminate tumors can bolster the paraganglioma market growth.
Market Opportunity: Development of Novel Orphan Drugs
The discontinuation of Iobenguane I 131 due to adverse side effects and the lack of effects of tyrosine kinase inhibitors (TKIs) can provide new opportunities for pharmaceutical manufacturers. The approval of belzutifan for patients with advanced paraganglioma can open the doors for novel drugs. This requires large-scale clinical trials and the elimination of side effects found in previous formulations.
Market Challenge: High Toxicity Levels of Approved Drugs
The limited number of drugs being approved for the treatment of paraganglioma can pose hurdles for the market growth. Adverse effects of musculoskeletal pain and nausea, as well as their continuation till disease progression due to a lack of alternative therapies, can negatively impact the market growth. Furthermore, the paucity of drugs for the treatment of pediatric patients from ages 3 to 11 with paraganglioma is a major challenge for the market.
Analyst’s View
Recent Developments
Belzutifan, a selective HIF-2α inhibitor, developed by Merck, has been granted approval by the U.S. FDA for the treatment of paraganglioma on March 14, 2025.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :